



App4Independence

Support. Predict. Impact.

Digital therapeutic (DTx) for
Severe Mental Illness.


[A4i.me](https://a4i.me)



Amos Adler M.Sc CEO
amos@a4i.me

Dr. Sean Kidd, CSO
Sean.kidd@camh.ca

The Problem



A lack of engagement at critical moments in care **results in non-adherence, relapse & readmission** for Severe Mental Illness (SMI) Psychosis, Schizophrenia and Opioid Use Disorder.

A4i App4Independence

Solution: A4i is a patent pending, validated digital therapeutic mobile intervention and clinical portal.


A4i safely connects patients to each other and to their clinicians while using data to predict risk and scale care.

ML digital biomarker platform uses ambient data and natural language processing (NLP) data to predict risk.

Patent-pending tools for cognitive remediation and outcomes improvements.¹



Patient Engagement
Clinical Decision Support
AI Enabled Risk Detection



App4Independence

Engage, improve outcomes and detect relapse risk.



The screenshot shows a clinical portal interface for a patient named Dobby Bobby. The patient's details include phone number 6478797199, case manager(s) Hello There, access RSHUPw, status Active, and enrolled on Feb 20 2020. There are buttons for Patient Settings, Patient Feed, and Reset Linked Device. A 'Risk Items' section contains two items: 'Turn off to stop the user from seeing public posts' and 'A4i User Consents to Risk Notifications'. An 'Indicators' section shows four metrics: Medications (15%), Sleep (09h 25m), Mood (1.6), and Detections (100%). A 'Medications' table lists Latuda (lurasidone) with 14% adherence and 23/27 missed doses. An 'Add Reminders' section allows adding medication, appointment, or event reminders with fields for name, time, and day(s).

Clinical Portal: Proactive & Predictive Risk Detection & Care Coordination



Med adherence



Auditory
Hallucinations





Poor Sleep



Poor Mood

SMI Market & Schizophrenia

Beachhead California Provider Market



A4i™ Validation Progress

A4i Schizophrenia, Psychosis

Co-design and Early Beta



- A4i built and launched
- Codesign Prototyping
- Beta Test 10 patients

Open Label Feasibility (Pre-Post, 1Mo, N=38)




- Brief Symptom Inventory - Improvements
- Controlling for age/gender (p<.01) reduction
- In depressive, obsessive compulsive and paranoid sx's
- More unwell=Higher engagement
- Low Churn, good qualitative outcomes
- Analysis validated 2022 via ML modelling

Randomize Control Trial (A4i vs. TAU, N= 45/arm)



- Single blind RCT
- User and provier metrics: Engagement, retention
- Symptoms: PANSS, BSI
- Treatment Adherence
- Treatment Alliance & QOL

Audio Hallucination Detector, Dig Phenotype

Feasibility and outcomes of a multi-function mobile health approach for the schizophrenia spectrum: App4Independence (A4i)

A4i-O (Opioid Use Disorder)

Co-design and Early Beta



- A4i-O Built and Launched
- Stakeholder input & User focus groups
- Open Label Pilot N=15
- BARS, medication adherence,
- (MOS), appointments attended

Open Label Pilot Pre-Post, 1 Mo N=15




- Usability, frequency, nature of use
- Patient Satisfaction
- Safety Review

Feasibility Randomized Control Trial (A4i-O vs. TAU, N=30/arm)



- Usability, frequency, nature of use
- Patient Satisfaction
- Safety Review



Predicting symptom response and engagement in a digital intervention among individuals with schizophrenia and related psychoses.

Clinical & Market Validation

CALIFORNIA PAID PILOT CaIMHSA



+84%

Patient Retention

+70%

Engagement

+20%

QOL Pre/Post

- ↑ Certified Peer Support Workers Reimbursement Revenue \$
- ↑ Remote Patient Monitoring + Virtual care Revenue Increases
- ↓ Readmission Reduction

RENEWED and EXPANDED for 2 extra years



The A4i Team



CEO



Amos Adler, M.Sc.

10 years Digital Health
Commercialization



CSO



Dr. Sean Kidd PhD

Division Chief Psychology CAMH,
Assoc. Prof Psychiatry UofT



Product



Wenjia Zhou, MHI

5 Years in evidence informed
design, clinical.




Digital SMI Competitive

Key A4i Differentiators

- Clinical Decision Support (SaaS)
- Patents Pending
- Validation Progress
- Engagement Focus
- Connected
- Data Science

Standalone

Connected



- ✓ Clinical Origins
- ✓ Data Science/Biomarker
- ✓ Clinical Decision Support
- ✓ Patents Pending

Competitor validation: Primarily academic small sample sizes. Short duration of study (1 month) + limited interpretation of clinical outcomes. Two studies did not include control groups and several studies noted no changes in primary and secondary clinical outcomes. Standalone with no digital biomarker strategy noted.

Business Model



Paid Pilots extended



Paid Pilots underway negotiating procurement



Early scaling and state showcase from pilot



LOI Obtained



New Ontario Hospital Contract announcement in April

Business Model:


1. SaaS: Per active patient per month & PMPM
2. Monthly hosting, analytics, support
3. Provider reimbursement transaction fees: Certified Peer Support, RPM, Tele-mental health

Provider ROI =

- virtual care enablement
- remote patient monitoring
- value-based care (readmission reduction)


Pilot ARR doubling annually 2020-2023

A4i \$1.5M SEED



A4i is raising \$1.5M (CAD) seed financing for milestones.

- ✓ Randomize Control Trial Results Summer 2023
- ✓ FDA Presubmission for audio hallucination detector
- ✓ 3-5 Additional Paid Pilots by Q1 2024
- ✓ Follow On Indication OUD Trial Q1 2024



Funding History: \$900K
Primarily Non-Dilutive

Thank You...




Amos Adler M.Sc.: CEO
amos@a4i.me
416-520-3301



JMIR Publications
Advancing Digital Health & Open Science



Johnson & Johnson INNOVATION JLABS



<https://www.a4i.me>